Monograph Details
|
|
Ob/Gyn
> Contraception
|
|
YASMIN |
| Manufacturer |
|
Bayer Corp, Pharmaceutical Div. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Progestin + estrogen. |
| Generic Name |
|
Drospirenone 3mg, ethinyl estradiol 30micrograms (21 tabs); inert (7 tabs). |
| Indications |
|
Oral contraception. |
| Children |
|
Not applicable. |
| Adults |
|
1 tab daily for 28 days; repeat. |
| Contraindications |
|
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Renal, hepatic, or adrenal insufficiency. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X). |
| Precautions |
|
Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Monitor K+ during 1st cycle if risk of hyperkalemia. Nursing mothers: not recommended. |
| Interactions |
|
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels. Monitor K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, angiotensin receptor blockers, NSAIDs, K+ sparing diuretics). |
| Adverse Reactions |
|
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders. |
| How Supplied |
|
Packs—3 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
